Merck & Co., Inc. (MRK)
| Market Cap | 376.37B +78.0% |
| Revenue (ttm) | 66.57B +4.6% |
| Net Income | 3.17B -80.7% |
| EPS | 1.27 -80.4% |
| Shares Out | 2.47B |
| PE Ratio | 119.85 |
| Forward PE | 17.70 |
| Dividend | $3.40 (2.23%) |
| Ex-Dividend Date | Sep 15, 2026 |
| Volume | 15,974,891 |
| Open | 149.12 |
| Previous Close | 148.99 |
| Day's Range | 148.59 - 154.49 |
| 52-Week Range | 77.58 - 154.49 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 147.77 (-3.13%) |
| Earnings Date | Aug 4, 2026 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock produ... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $147.77, which is a decrease of -3.13% from the latest price.
News
Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?
This article was written by Doug Nathman, with research by his team at Trefis.
Moderna is paring back gains, but Merck stock remains a buy
Moderna (MRNA) shares are paring back some of their recent gains on Thursday morning – but a Morgan Stanley analyst believes Merck (MRK) stock remains a buy following blockbuster cancer drug trial res...
Thursday's First Moves: Analysts Mixed on MRNA & MRK Rally, AAP & DE Earnings
Diane King Hall discusses the sharp sell-off in Advance Auto Parts (AAP) as the guidance shows strong headwinds. Deere (DE) offered plenty of strength in its earnings as construction revenues rise.
Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data
Moderna and Merck delivered positive news about their personalized skin-cancer vaccine Wednesday. Investors bought their shares in droves.
Moderna, Merck breakthrough could usher in wave of cancer vaccines
Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors.
Merck, Moderna Stocks Soar After Melanoma Trial Success
Shares of Moderna and Merck soared on Wednesday morning after a study showed that a vaccine they produced had promising results when it comes to fighting skin cancer. A late-stage trial showed that th...
VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results
Moderna's personalized mRNA cancer therapy, developed with Merck , reduced the risk of melanoma recurrence and spread when used in combination with the U.S. drugmaker's blockbuster treatment Keytruda...
Merck, Moderna Melanoma Vaccine Study Succeeds
Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin...
U.S. Treasury Boosts Debt Buybacks, UAE Cuts Off Iran, MRNA & MRK Melanoma Trial Results
The U.S. Treasury is "at least" doubling debt buybacks for longer-dated nominal coupon securities, causing a surge in fixed income activity after yields hit highs not seen in years. Kevin Hincks expla...
'An increased ability to disease-free': Moderna CEO & Merck's Dr. Li on skin cancel vaccine trial
Stephane Bancel, Moderna CEO, and Dr. Dean Li, Merck Research Laboratories president, join 'Squawk Box' to discuss details of an experimental personalized cancer vaccine that showed positive initial r...
Moderna, Merck, La-Z-Boy, SK Hynix, and More Stocks That Explain Today's Market
Stock markets are waited on minutes of the Fed's most recent monetary policy meeting for any clues about the forward path on interest rates.
Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
Merck and Moderna said on Wednesday a study of a personalized mRNA vaccine combined with the immunotherapy drug Keytruda reduced melanoma skin cancer recurrence and spread compared with Keytruda alo...
Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
An experimental personalized cancer vaccine from Merck and Moderna showed positive initial results in its first-ever late-stage trial. The combination regimen met the main study goal of significantly ...
An experimental mRNA-based cancer vaccine succeeded in preventing melanoma from coming back or spreading in a large study, partners Merck and Moderna said.
Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced positive topline results fro...
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Sarah Cannon Research Institute and Merck Collaborate to Expand Access to Oncology Clinical Trials
NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI) announced a strategic collaboration with Merck to utilize SCRI's Accelero™ delivery model.
Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences
President Donald Trump's latest executive order calls for splitting the measles, mumps and rubella, or MMR, vaccine into three separate shots. But doctors and other experts say that effort has no scie...
U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a su...
Merck & Co. Earnings Call Transcript: Q2 2026
Q2 revenue rose 5% to $16.6B, led by oncology, animal health, and new launches. Guidance for 2026 was raised, with EPS expected at $2.66–$2.76, including a $2.31/share one-time charge. Major regulatory approvals and pipeline advances de-risk future growth.
Merck & Co. Earnings release: Q2 2026
Merck & Co. released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Merck & Co. Slides: Q2 2026
Merck & Co. has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Merck & Co. Quarterly report: Q2 2026
Merck & Co. has published its Q2 2026 quarterly earnings report on August 4, 2026.
Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Line
Merck slashed its profit outlook for the year due to charges tied to its acquisition of cancer biotech company Terns Pharmaceuticals.